Skip to main content

Month: March 2026

PEDEVCO Announces Participation in the 38ᵗʰ Annual ROTH Conference

HOUSTON, March 20, 2026 (GLOBE NEWSWIRE) — PEDEVCO Corp. (NYSE American: PED) (“PEDEVCO” or the “Company”), a domestic energy company engaged in the acquisition and development of strategic, high growth energy projects in the Rocky Mountain region, today announced that President & Chief Executive Officer J. Douglas Schick, Chief Operating Officer Reagan Tuck (R.T.) Dukes, and Executive Vice President & General Counsel Clark Moore, will participate in the 38th Annual Roth Conference taking place March 22–24, 2026. Members of management will host investor meetings on-site during the conference. An updated investor presentation is available on the Company’s website at https://www.pedevco.com/investors. Full event details are listed below. 38th Annual ROTH ConferenceDana Point, CaliforniaMarch 22-24, 2026 About PEDEVCO Corp.PEDEVCO...

Continue reading

Rezolve Ai and Microsoft to Spotlight the Rise of Agentic Commerce at the 38th Annual Roth Conference

NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), the company pioneering Agentic Commerce for retail, today announced that its Founder and Chief Executive Officer, Daniel M. Wagner, will participate in a fireside chat alongside Vic Miles, Americas General Manager, Retail and Consumer Goods Industry solutions at Microsoft, on Tuesday, March 24, 2026 at 1:00 p.m. Pacific Time / 4:00 p.m. Eastern Time. The discussion will focus on the emergence of Agentic Commerce and the growing strategic partnership between Rezolve Ai and Microsoft as retailers seek AI-powered solutions that drive smarter consumer engagement, stronger conversion and more efficient digital commerce. Fireside Chat DetailsTitle: The Age of Agentic Commerce – Challenges and Opportunities with Microsoft and RezolveDate: Tuesday, March 24, 2026Time:...

Continue reading

VisionWave Holdings Establishes Israeli Subsidiary and Appoints Leadership Team to Advance Strategic Technology Platform

WEST HOLLYWOOD, Calif., March 20, 2026 (GLOBE NEWSWIRE) — VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”), a developer of advanced AI-driven sensing, RF, and defense-related technologies, today announced the establishment and full acquisition of VisionWave IL Ltd., a wholly owned subsidiary based in Israel for nominal consideration. The Company has appointed Khdoura Sabbagh (A/K/A Adir Sabag) as Chief Executive Officer and sole director of VisionWave IL Ltd., and engaged Oren Attiya, through CO-Finance Financial and Accounting Consulting Ltd., to provide financial leadership and CFO-level services to the subsidiary. Strategic Expansion into Israel – The formation of VisionWave IL Ltd. represents an initial step in the Company’s continued expansion of its global operational footprint, positioning VisionWave...

Continue reading

Gauzy Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

No Impact to Ongoing Operations or Trading; Company Evaluating All Options to Address Requirement Within Compliance Period TEL AVIV, Israel, March 20, 2026 (GLOBE NEWSWIRE) — Gauzy Ltd. (Nasdaq: GAUZ) (“Gauzy” or the “Company”), a global leader in vision and light control technologies, today announced that on March 17, 2026 it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1). The notification was issued because the closing bid price of the Company’s ordinary shares was below $1.00 per share for 30 consecutive business days, which is the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). The notice has...

Continue reading

Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 26, 2026, to review its financial results for the year ended December 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 1717423. The live webcast can be accessed under “Presentations, Events & Webcasts” in the Investors section of the company’s website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install...

Continue reading

VenHub Advances Autonomous Smart Store Security to Tackle Rising Retail Industry Theft and Shrink

LAS VEGAS, March 20, 2026 (GLOBE NEWSWIRE) — VenHub Global, Inc. (NASDAQ: VHUB) (“VenHub” or the “Company”), a leader in fully autonomous Smart Store technology, today highlighted its expansive portfolio of new retail security-focused technologies that are helping to address the many billions of dollars in losses impacting the industry. The six new innovations highlighted are solutions that advance the Company’s Smart Store functionality across the “Advanced Security & Protection Systems” category. “We are focused on technology innovations for our Smart Stores that address the challenges of traditional retail to empower consumers with an easy and enjoyable shopping experience while also providing quantifiable financial benefits for our Smart Store operators,” said Shahan Ohanessian, CEO at VenHub. “Theft and product shrinkage...

Continue reading

New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease

Findings underpin potential of Anavex’ lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy restoration NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that a new peer-reviewed study published by University of California in Proceedings of the National Academy of Sciences, Nexus1 (Shoff et al., 2026) supports the hypothesis that disruption of neuronal homeostasis—particularly autophagy impairment—acts upstream of amyloid...

Continue reading

DEEP SEA MINERALS CORP. SUBMITS RESPONSE TO U.S. DEFENSE INDUSTRIAL BASE CONSORTIUM SOLICITATION FOR CRITICAL MINERALS

Vancouver, BC, March 20, 2026 (GLOBE NEWSWIRE) — Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X45) (“Deep Sea Minerals” or the “Company”), a subsea mineral exploration and development company focused on advancing critical mineral opportunities from the deep ocean, is pleased to announce that it has submitted its bid in response to a solicitation from the U.S. Defense Industrial Base Consortium (the “DIBC”) to provide to the United States a reliable supply of critical minerals, focusing on Nickel (Ni), and a complementary commercialization plant. In February 2026, the DIBC issued a new request for project proposal (“RPP”) focused on strategic critical minerals. The DoW has prioritized identification of supply chain alternatives for defense-critical minerals used in the production of aircraft, missiles,...

Continue reading

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVT Participants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placebo CARDAMYST launch execution on track with positive initial engagement in the product from healthcare providers and payers $200 million pro forma cash supports strong launch and operating runway into late 2027; includes $106 million of cash at year-end and net proceeds from subsequent financing activities1 Company to host investor call and webcast at 8:30am ET todayMONTREAL and CHARLOTTE, N.C., March 20, 2026 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization...

Continue reading

Baker Hughes Announces Dates for First-quarter Earnings Release and Webcast 

HOUSTON and LONDON, March 20, 2026 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR) will announce the results of the first quarter ending March 31, 2026, via press release at 5 p.m. Eastern Time (4 p.m. Central Time) on Thursday, April 23, 2026. A webcast to discuss the results will be held Friday, April 24, at 9:30 a.m. Eastern Time (8:30 a.m. Central Time). To access the webcast, listeners should visit the Baker Hughes website at: investors.bakerhughes.com. An archived version will be available on the website following the webcast. About Baker HughesBaker Hughes (NASDAQ: BKR) is an energy technology company that provides solutions to energy and industrial customers worldwide. Built on a century of experience and conducting business in over 120 countries, our innovative technologies and services are taking energy forward – making...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.